ICRA upgrades drug companies as China reopens

When Icra revised the rating earlier this year, the fear was that a shutdown in China prompted by the Covid-19 pandemic would block key active pharmaceutical ingredients (APIs) from coming into the country. APIs are the basic ingredients for drugs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3d1oKSm
via IFTTT